Madrigal Pharmaceuticals, Inc. MDGL Business Segments — Net loss
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The official record: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Madrigal Pharmaceuticals, Inc.'s business segments — net loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Madrigal Pharmaceuticals, Inc.'s business segments — net loss?
- Madrigal Pharmaceuticals, Inc. (MDGL) reported business segments — net loss of -$94.39M in Q1 2026.
- How has Madrigal Pharmaceuticals, Inc.'s business segments — net loss changed year-over-year?
- Madrigal Pharmaceuticals, Inc.'s business segments — net loss decreased by 28.9% year-over-year, from -$73.24M to -$94.39M.
- What is the long-term trend for Madrigal Pharmaceuticals, Inc.'s business segments — net loss?
- Over 2 years (2023 to 2025), Madrigal Pharmaceuticals, Inc.'s business segments — net loss has grown at a -12.2% compound annual growth rate (CAGR), from -$373.63M to -$288.28M.
- What does business segments — net loss mean?
- The total loss generated by the business segment after all expenses.
- How do you interpret business segments — net loss?
- A narrowing loss indicates progress toward profitability or improved operational efficiency.
- How does business segments — net loss compare across companies?
- Standard measure of segment-level profitability or burn rate.